Search results for "immunosuppressive agent"

showing 10 items of 282 documents

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1999

No established medical therapy alters the progressive course of primary sclerosing cholangitis.To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis.Case series.University hospital in Mainz, Germany.15 patients with primary sclerosing cholangitis.Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day).Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a30% change in stenosis was considered significant).After a median observation period of 41 months (ran…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPrednisolonemedicine.medical_treatmentCholangitis SclerosingPilot ProjectsAzathioprineAutoimmune hepatitisGastroenterologyInflammatory bowel diseasePrimary sclerosing cholangitisInternal medicineAzathioprineInternal MedicinemedicineHumansChemotherapybusiness.industryUrsodeoxycholic AcidGeneral Medicinemedicine.diseaseUlcerative colitisUrsodeoxycholic acidSurgeryRadiographyLiverPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugAnnals of Internal Medicine
researchProduct

Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.

2019

Background: Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018. Objective and Methods: This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy. Results: Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7). Secondary autoimmune diseases developed. Blood analysis reveale…

AdultMaleDaclizumabMultiple Sclerosismedicine.drug_classMonoclonal antibodyAutoimmune Diseases03 medical and health sciences0302 clinical medicineDaclizumabmedicineHumansLymphocytes030304 developmental biologyRetrospective Studies0303 health sciencesbusiness.industryMultiple sclerosisMeningoencephalitisAntibodies MonoclonalBrainMiddle Agedmedicine.disease3. Good healthNeurologyImmunologyEncephalitisFemaleNeurology (clinical)business030217 neurology & neurosurgeryEncephalitisImmunosuppressive Agentsmedicine.drugMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Autoimmune hepatitis following Epstein-Barr virus infection

2008

We describe a case of a young man with autoimmune hepatitis (AIH) following Epstein–Barr virus (EBV) infection, in whom a long follow-up showed favourable outcome with complete clinical recovery and failure to relapse after cessation of immunosuppressive therapy. The study underlines the importance of the differential diagnosis between primary EBV associated hepatitis with features of autoimmunity, in which there is a direct pathogenetic role of the virus, and EBV related AIH, in which EBV could act as the trigger of the immune mediated damage with probable differences between the two conditions with regard to the prognosis and the responsiveness to immunosuppressive treatment. The favourab…

AdultMaleEpstein-Barr Virus InfectionsHepatitis Viral HumanAnti-Inflammatory AgentsAzathioprineDiseaseAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeMethylprednisoloneArticleVirusAutoimmunityDiagnosis Differentialimmune system diseaseshemic and lymphatic diseasesAzathioprinemedicineHumansEpstein–Barr virus infectionHepatitisbusiness.industryGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneLiverImmunologyDrug Therapy CombinationEBV autoimmune hepatitisDifferential diagnosisbusinessImmunosuppressive Agentsmedicine.drugCase Reports
researchProduct

Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series.

2013

AdultMaleHeredityAdolescentIntracellular Signaling Peptides and Proteinsautoinflammatory disorder phenotype NLRP12TRAPSMiddle AgedCryopyrin-Associated Periodic SyndromesPedigreePhenotypeTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyMutationHumansFemaleGenetic Predisposition to DiseaseAdolescent; Adult; Child Preschool; Cryopyrin-Associated Periodic Syndromes; Female; Genetic Predisposition to Disease; Heredity; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Italy; Male; Middle Aged; Pedigree; Phenotype; Treatment Outcome; MutationChildPreschoolImmunosuppressive Agents
researchProduct

Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation

2009

BACKGROUND: Invasive pneumococcal disease is a life-threatening complication after allogeneic stem cell transplantation, and at least 20% of cases occur within 1 year after transplantation. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has limited efficacy, especially during the first year after transplantation. The immune response to the conjugated vaccines is expected to be better than that to the polysaccharide vaccine, but the optimal timing of vaccination is not defined. Our objective was to show that a 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) was not inferior when first given 3 months after transplantation, compared with when first given 9 months after trans…

AdultMaleMicrobiology (medical)Pediatricsmedicine.medical_specialtyHeptavalent Pneumococcal Conjugate VaccineTime FactorsAdolescentmedicine.medical_treatmentImmunization SecondaryHematopoietic stem cell transplantationPneumococcal conjugate vaccinePneumococcal VaccinesYoung AdultHeptavalent Pneumococcal Conjugate VaccineHumansMedicineChildImmunization Schedulebusiness.industryPneumococcal 7-Valent Conjugate VaccineMiddle AgedAntibodies BacterialPneumococcal polysaccharide vaccineEuropeVaccinationTransplantationInfectious DiseasesImmunizationImmunologyFemalebusinessImmunosuppressive AgentsStem Cell Transplantationmedicine.drugClinical Infectious Diseases
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

2015

Objective: We aimed to clarify whether fingolimod has direct effects on antigen-presenting cells in multiple sclerosis patients. Methods: Frequency and phenotype of directly ex vivo dendritic cells and monocytes were analyzed in 43 individuals, including fingolimod-treated and untreated multiple sclerosis patients as well as healthy subjects. These cells were further stimulated with lipopolysaccharide to determine functional effects of fingolimod treatment. Results: Absolute numbers of CD1c+ dendritic cells and monocytes were not significantly reduced in fingolimod-treated patients indicating that fingolimod did not block the migration of antigen-presenting cells to peripheral blood. CD86 w…

AdultMaleMultiple Sclerosismedicine.medical_treatmentMonocytesYoung AdultMedicineHumansAntigen-presenting cellCD86business.industryFingolimod HydrochlorideMonocyteDendritic cellImmunotherapyDendritic CellsMiddle AgedFingolimodCytokinemedicine.anatomical_structureNeurologyImmunologyCytokinesFemaleNeurology (clinical)businessEx vivoImmunosuppressive Agentsmedicine.drugMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Trans…

2019

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%) were all…

AdultMaleOncologymedicine.medical_specialtyPremedicationmedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationAntiviral AgentsAllogeneic hematopoietic stem cells transplantationMechanistic target of rapamycin inhibitorQuantitative PCR03 medical and health sciences0302 clinical medicineTime-to-event analysisInternal medicineHumansTransplantation HomologousMedicineCumulative incidenceCytomegalovirus diseaseSurvival analysisRetrospective StudiesSirolimusTransplantationDose-Response Relationship Drugbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationPK/PDvirus diseasesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseCytomegalovirus infectionsurgical procedures operativeCytomegalovirus DNAemia030220 oncology & carcinogenesisSirolimusCytomegalovirus InfectionsPreemptive antiviral therapySirolimus exposureFemalebusinessSerostatusImmunosuppressive Agents030215 immunologymedicine.drug
researchProduct

Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.

1996

Abstract Background/Aims: Autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis are chronic liver diseases with probable autoimmune background. Overlapping features have been described for primary biliary cirrhosis and autoimmune hepatitis. In contrast, there have been only a few case reports on an overlap of autoimmune hepatitis and primary sclerosing cholangitis. Methods: We describe three male patients with clinical and histological overlapping features of primary sclerosing cholangitis and autoimmune hepatitis. Results: All initially asymptomatic patients had elevated levels of aminotransferases, alkaline phosphatase, γ-glutamyltranspeptidase and IgG. Anti-n…

AdultMalePathologymedicine.medical_specialtyCirrhosisAdolescentBiopsyCholangitis SclerosingAutoimmune hepatitisGastroenterologyPrimary sclerosing cholangitisAutoimmune DiseasesDiagnosis DifferentialPrimary biliary cirrhosisInternal medicinemedicineHumansTransaminasesHepatitis ChronicHepatitisAutoimmune diseaseCholangiopancreatography Endoscopic RetrogradeHepatologyBile ductbusiness.industryOverlap syndromeSyndromemedicine.diseasemedicine.anatomical_structureAntibodies AntinuclearImmunoglobulin GbusinessImmunosuppressive AgentsFollow-Up StudiesJournal of hepatology
researchProduct

A Follicular Dendritic Cell Sarcoma of the Mediastinum With Immature T Cells and Association With Myasthenia Gravis

2010

Follicular dendritic cell (FDC) sarcoma is a very rare neoplasm showing morphologic and phenotypic features of FDCs. It occurs primarily in lymph nodes but also in extranodal sites. So far, there have been no reports on FDC sarcoma associated with myasthenia gravis. In the following we will present a case of an FDC tumor of the mediastinum associated with paraneoplastic myasthenia gravis in a 39-year-old man. The tumor contained a major proportion of immature T cells, which may be connected to this patient's very unusual clinical presentation with autoimmune phenomena. Extranodal FDC sarcomas still seem hardly noticed, and their clinical and pathologic characteristics remain to be better de…

AdultMalePathologymedicine.medical_specialtyT-LymphocytesDendritic Cell Sarcoma FollicularMediastinal NeoplasmsFollicular cellPathology and Forensic MedicineAzathioprineMyasthenia GravisBiomarkers TumormedicineHumansAntigen-presenting cellFollicular dendritic cellsbusiness.industryMediastinumDendritic cellThymectomymedicine.diseaseImmunohistochemistryMyasthenia gravismedicine.anatomical_structureFollicular dendritic cell sarcomaSurgeryLymph NodesSarcomaAnatomybusinessImmunosuppressive AgentsAmerican Journal of Surgical Pathology
researchProduct